Future microbiology最新文献

Assessing antimicrobial resistance in Shiga toxin-producing Escherichia coli O157 isolates from human clinical cases in the United States, 2010-2021. 2010-2021年美国人类临床病例中产志贺毒素大肠杆菌O157分离株的抗菌素耐药性评估

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-05-09 DOI: 10.1080/17460913.2026.2671606

Tarjani Bhatt, Csaba Varga

{"title":"Assessing antimicrobial resistance in Shiga toxin-producing Escherichia coli O157 isolates from human clinical cases in the United States, 2010-2021.","authors":"Tarjani Bhatt, Csaba Varga","doi":"10.1080/17460913.2026.2671606","DOIUrl":"https://doi.org/10.1080/17460913.2026.2671606","url":null,"abstract":"Aims: To characterize antimicrobial resistance (AMR) patterns and temporal trends among Shiga toxin-producing Escherichia coli O157 (STEC O157) clinical isolates from humans in the United States.Patients and methods: 1,995 STEC O157 isolates collected from cases between 2010 and 2021 were analyzed. Resistance to antimicrobials was assessed, and temporal trends were evaluated using the Mann-Kendall test. Associations between AMR and demographic factors, including age and region, were examined using logistic regression models.Results: Resistance was most common to tetracycline (12.4%) and sulfisoxazole (9.9%), with temporal increases observed in resistance for these agents, along with chloramphenicol and trimethoprim-sulfamethoxazole (Mann-Kendall tau = 0.69-0.87, p < 0.001). Regional differences in AMR were noted for tetracycline, trimethoprim-sulfamethoxazole, and chloramphenicol. Cases aged 20-39 had higher odds of resistance to trimethoprim-sulfamethoxazole compared to those aged 0-4.Conclusions: Since antimicrobials are not recommended for treating STEC O157 infections in humans, the sources of resistant strains could be foodborne, direct animal contact, the environment, or treatment for bacterial coinfections. The increase in the prevalence of AMR among STEC O157 strains in humans warrants investigation into the factors driving the emergence of resistant isolates. These findings call for an \"One Health\" approach for antimicrobial stewardship to mitigate AMR risks.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"1-11"},"PeriodicalIF":2.4,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adaptive strategies of Staphylococcus aureus: Deciphering the virulence and antibiotic tolerance mechanisms under multifaceted stress conditions. 金黄色葡萄球菌的适应策略：解读多方面应激条件下的毒力和抗生素耐受机制。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-21 DOI: 10.1080/17460913.2026.2661258

Suvetha Selvam, Srijanani Bharath Meenakumari, Fazlurrahman Khan, Arun Kumar Mani

引用次数: 0

Spore-casting outcomes: Histoplasma serology in lung nodule risk stratification. 孢子铸造结果：肺结节危险分层的组织浆血清学。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-28 DOI: 10.1080/17460913.2026.2665041

Nicholas D Nassif, Elena K Roberts, Sheryl-Phuc N Vu, Keenan W Taylor

{"title":"Spore-casting outcomes: Histoplasma serology in lung nodule risk stratification.","authors":"Nicholas D Nassif, Elena K Roberts, Sheryl-Phuc N Vu, Keenan W Taylor","doi":"10.1080/17460913.2026.2665041","DOIUrl":"10.1080/17460913.2026.2665041","url":null,"abstract":"Background: Lung nodule evaluation is a vital practice in pulmonary medicine. While biopsy remains the diagnostic gold standard, it carries procedural risks. In regions endemic for fungal disease, low-cost, noninvasive testing may help reduce unnecessary procedures.Aim: We seek to evaluate the association between positive endemic histoplasma antibody titers and non-cancerous pathology in patients with pulmonary nodules. Methods: We conducted a simple, retrospective, single-center study of patients diagnosed with solitary (R91.1) or multiple (R91.8) pulmonary nodules. Data collected included Histoplasma antibody results, pathologic diagnoses when available, PET-CT, and clinical course (follow-up CT scans).Results: Positive Histoplasma antibody testing demonstrated an inverse relationship with malignant pathology. However, this association did not reach statistical significance. Conclusions: Histoplasma antibody titers may help identify patients with pulmonary nodules who are less likely to have malignancy, potentially supporting conservative monitoring over biopsy in selected cases. Larger, prospective studies are needed to determine the clinical utility of fungal testing in lung nodule management.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"423-428"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antimicrobial resistance in Ecuador: lessons from the 2019-2023 plan and future directions. 厄瓜多尔的抗菌素耐药性：2019-2023年计划的教训和未来方向。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-15 DOI: 10.1080/17460913.2026.2659528

Valeria Torres-Espín, Carlos Bastidas-Caldes

引用次数: 0

Meta-analysis of preclinical evidence supporting phage therapy against Stenotrophomonas maltophilia. 支持噬菌体治疗嗜麦芽窄养单胞菌临床前证据的荟萃分析。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-05-06 DOI: 10.1080/17460913.2026.2667121

Hamid Sadeghi, Saeideh Gholamzadeh Khoei, Amir Javadi, Mehdi Bakht, Masoumeh Aslanimehr, Farhad Nikkhahi

{"title":"Meta-analysis of preclinical evidence supporting phage therapy against Stenotrophomonas maltophilia.","authors":"Hamid Sadeghi, Saeideh Gholamzadeh Khoei, Amir Javadi, Mehdi Bakht, Masoumeh Aslanimehr, Farhad Nikkhahi","doi":"10.1080/17460913.2026.2667121","DOIUrl":"https://doi.org/10.1080/17460913.2026.2667121","url":null,"abstract":"Aim: To systematically and quantitatively assess the efficacy of phage therapy against multidrug-resistant Stenotrophomonas maltophilia in preclinical models.Materials and methods: A systematic search of PubMed, Scopus, ScienceDirect, Google Scholar, and Wiley Online Library was conducted for preclinical studies on phage therapy against established S. maltophilia infections with survival outcomes. Data were pooled using a fixed-effects model, with subgroup and sensitivity analyses.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD420251059693.Results: Among 6,277 references, six studies met the inclusion criteria; one study was excluded after sensitivity analysis. The overall pooled Odds Ratio (OR) for phage therapy efficacy was 21.10 (95% CI: 9.09-49.02; p < 0.001). Subgroup analysis by Multiplicity of Infection (MOI) showed dose-dependent effects, with the highest efficacy at MOI = 100 (OR =143.68, 95% CI: 11.95-1726.78; p < 0.001) followed by MOI = 10 (OR =60.13, 95% CI: 6.29-575.09; p < 0.001). Burst size analysis indicated larger burst sizes increased effect magnitude, with the highest at 41.67 (OR =31.27, 95% CI: 7.32-133.49; p < 0.001).Conclusion: Phage therapy shows strong preclinical efficacy against multidrug-resistant S. maltophilia. It represents a rapid, targeted, and antibiotic-sparing approach, supporting future antimicrobial stewardship efforts and informing the design of clinical applications.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":"21 5","pages":"483-491"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reassessing the reliability and translational potential of bacterial cell envelope targets: lessons from LpxC, NagA, and beyond. 重新评估细菌细胞包膜靶点的可靠性和转化潜力：来自LpxC， NagA等的经验教训。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-15 DOI: 10.1080/17460913.2026.2659493

Ahmed M Kamal El-Sagheir, Alaa Elsaghir

{"title":"Reassessing the reliability and translational potential of bacterial cell envelope targets: lessons from LpxC, NagA, and beyond.","authors":"Ahmed M Kamal El-Sagheir, Alaa Elsaghir","doi":"10.1080/17460913.2026.2659493","DOIUrl":"10.1080/17460913.2026.2659493","url":null,"abstract":"Despite major advances in antibacterial target identification, the translation of biochemically validated targets into clinically effective therapies remains inconsistent, particularly for Gram-negative pathogens. Enzymes involved in bacterial cell envelope biogenesis, such as LpxC and NagA, exemplify this disconnect. Both targets are genetically validated, structurally tractable, and extensively characterized, yet no inhibitors have reached clinical use. Here, we argue that this gap reflects limitations in early target assessment rather than intrinsic flaws in these enzymes. Using LpxC and NagA as case studies, we highlight how context-dependent essentiality, metabolic adaptability, pathway robustness, host microenvironments, and pharmacokinetic constraints collectively shape translational outcomes. We further discuss systems-level and computational approaches that expose adaptive buffering and compensatory mechanisms overlooked by classical validation paradigms. Finally, we propose a reliability-based framework for antibacterial target prioritization that integrates physiological indispensability, pathway fragility, bypass potential, and translational feasibility. Incorporating reliability-driven criteria early in discovery may improve target selection and reduce late-stage attrition in antibacterial drug development.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"443-451"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147689499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antifungal resistance and Ocimum gratissimum L. essential oil-clotrimazole interactions in clinical Candida isolates from Vietnam. 越南临床假丝酵母菌分离株的抗真菌耐药性及其精油与克霉唑的相互作用。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-28 DOI: 10.1080/17460913.2026.2665051

Dang Anh Tuan, Jan Masak

{"title":"Antifungal resistance and Ocimum gratissimum L. essential oil-clotrimazole interactions in clinical Candida isolates from Vietnam.","authors":"Dang Anh Tuan, Jan Masak","doi":"10.1080/17460913.2026.2665051","DOIUrl":"10.1080/17460913.2026.2665051","url":null,"abstract":"Aims: To describe Candida species distribution and antifungal susceptibility in a Vietnamese tertiary-hospital collection and to evaluate Ocimum gratissimum L. essential oil (OGEO) as an in-vitro adjunct to clotrimazole.Materials and methods: We retrospectively analysed 423 clinical Candida isolates collected in 2017-2018. Species identification used routine phenotypic methods/VITEK 2; susceptibility to fluconazole, voriconazole, and amphotericin B followed CLSI M27-A3. OGEO was chemically profiled by GC-MS. Crystal violet assays assessed OGEO inhibition of biofilm formation in 30 C. albicans isolates, and checkerboard assays evaluated OGEO-clotrimazole interactions in 20 species-resolved isolates using FICI.Results: Species-level identification was available for 212 isolates; C. tropicalis (25.8% of the full cohort) slightly exceeded C. albicans (21.8%), while 49.8% were recorded as Candida spp. Overall fluconazole resistance was 13.7%, with higher resistance in C. tropicalis than C. albicans. OGEO was eugenol-rich (66.7%) and inhibited C. albicans biofilm biomass by 71.2% at 1% and 89.6% at 2% v/v. OGEO-clotrimazole interactions were FICI-defined synergistic in 65%, additive in 30%, indifferent in 5%, and never antagonistic.Conclusion: OGEO showed promising in-vitro anti-biofilm and clotrimazole-potentiating activity, supporting further standardized, species-matched, topical-formulation and safety studies.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"429-442"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel antibacterials targeting multidrug-resistant gram-positive and gram-negative bacteria: an updated review. 针对多重耐药革兰氏阳性和革兰氏阴性细菌的新型抗菌药物：最新综述。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-19 DOI: 10.1080/17460913.2026.2661277

Yusuf Emre Ozdemir, Serkan Surme, Meryem Sahin Ozdemir, Khalis Mustafayev

{"title":"Novel antibacterials targeting multidrug-resistant gram-positive and gram-negative bacteria: an updated review.","authors":"Yusuf Emre Ozdemir, Serkan Surme, Meryem Sahin Ozdemir, Khalis Mustafayev","doi":"10.1080/17460913.2026.2661277","DOIUrl":"10.1080/17460913.2026.2661277","url":null,"abstract":"The 2024 World Health Organization (WHO) bacterial priority pathogens list highlights third-generation cephalosporin-resistant and carbapenem-resistant Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and rifampicin-resistant Mycobacterium tuberculosis as critical targets. Despite global efforts, antibiotic development remains limited, with 97 agents in the pipeline by 2023, one-third of which are directed against drug-resistant M. tuberculosis. Relevant data on novel antibacterial agents were identified through searches of the Scopus, PubMed, and Web of Science databases, as well as the 2024 WHO report on new and emerging antibiotics, focusing on studies published within the past 5 years. This review summarizes novel antibacterial agents targeting resistant Gram-negative and Gram-positive pathogens, including compounds that are currently under Food and Drug Administration evaluation or recently approved, as well as additional promising candidates under development for the treatment of drug-resistant microorganisms. In addition, a brief overview of the non-traditional agents that have completed the approval process and are now available on the market is also provided.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"465-481"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147722477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of eravacycline in combating multidrug-resistant bacterial infections: insights into efficacy, emerging resistance, and clinical safety. 依拉瓦环素在对抗多药耐药细菌感染中的作用：对疗效、新出现的耐药性和临床安全性的见解。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-23 DOI: 10.1080/17460913.2026.2661231

Dawei Liang, Yongyi Yan, Guoda Wu, Jianci Huang, Minjie Xie, Yuying Tan, Jinhua Wu

{"title":"The role of eravacycline in combating multidrug-resistant bacterial infections: insights into efficacy, emerging resistance, and clinical safety.","authors":"Dawei Liang, Yongyi Yan, Guoda Wu, Jianci Huang, Minjie Xie, Yuying Tan, Jinhua Wu","doi":"10.1080/17460913.2026.2661231","DOIUrl":"10.1080/17460913.2026.2661231","url":null,"abstract":"The global rise of multidrug-resistant bacteria, including carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Acinetobacter baumannii (CRAB), methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococcus spp (VRE), poses a major public health threat and complicates treatment. Eravacycline, a new synthetic fluorocycline antibiotic, shows strong in vitro effectiveness against various multidrug-resistant (MDR) Gram-positive and Gram-negative bacteria and anaerobes. Its unique structural modifications help it overcome common tetracycline resistance mechanisms. Real-world data show eravacycline achieves high cure and survival rates with low recurrence for infections by CRE, CRAB, MRSA, and VRE, though its effectiveness against Pseudomonas aeruginosa and Burkholderia cepacia is limited. Key resistance mechanisms in clinical isolates include efflux pump upregulation, ribosomal mutations, and plasmid-mediated tet(X) genes. Eravacycline is generally safe, causing fewer gastrointestinal issues than tigecycline and less nephrotoxicity than polymyxins. It doesn't require dosage adjustments for renal or mild-to-moderate hepatic impairment. Eravacycline is vital for treating MDR infections when traditional therapies fail. However, it is currently approved by the U.S. Food and Drug Administration specifically for parenteral administration in the treatment of complicated intra-abdominal infections. Therefore, more large-scale trials are needed to confirm its effectiveness, optimize combination therapies, and further address the MDR crisis.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"453-464"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mapping the evolving landscape of Staphylococcus aureus virulence: determinants, regulation, and new directions. 绘制金黄色葡萄球菌毒力演变的景观：决定因素、调控和新方向。

IF 2.4 4区生物学

Future microbiology Pub Date : 2026-04-01 Epub Date: 2026-04-22 DOI: 10.1080/17460913.2026.2661505

Zhanhua Tao, Ke Ke, Libo Zhu

{"title":"Mapping the evolving landscape of Staphylococcus aureus virulence: determinants, regulation, and new directions.","authors":"Zhanhua Tao, Ke Ke, Libo Zhu","doi":"10.1080/17460913.2026.2661505","DOIUrl":"10.1080/17460913.2026.2661505","url":null,"abstract":"Aims: Staphylococcus aureus pathogenicity depends on diverse virulence factors and regulators. However, the research trajectory of this field has not yet been quantitatively mapped.Materials and methods: We analyzed 16,899 Web of Science records (1990-2024) using bibliometrics to quantify output and impact, the normalized cumulative frequency (NCF), and a trend-factor metric for individual virulence determinants and regulators, and structural topic modeling (STM) to identify and track major themes.Results: S. aureus virulence increased more than sevenfold, with recent growth driven by emerging economies and expanding cross-disciplinary input. NCF and trend-factor analyses indicate that attention to classical toxins and core regulators has plateaued at a high level. Interest has shifted toward biofilm- and adaptation-linked factors and cell-envelope stress regulators, reflecting growing concern over chronic and antibiotic-tolerant infections. STM revealed seven dominant themes and showed sustained growth of biofilm- and regulation-focused topics, alongside a relative decline of foodborne and toxin-centric themes.Conclusions: This multi-level, data-driven map summarizes patterns in how attention to S. aureus virulence determinants, regulators, and thematic domains has evolved since 1990 and may inform future work on virulence mechanisms, anti-virulence, and anti-biofilm strategies, and clinically oriented research.","PeriodicalId":12773,"journal":{"name":"Future microbiology","volume":" ","pages":"407-422"},"PeriodicalIF":2.4,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147769692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0